IP Library Granted Patent US 11,534,600
Granted Patent B2
US 11,534,600 · App. 16/662,140 · Granted Dec 27, 2022

Non-invasive nerve stimulation to treat or prevent autism spectrum disorders and other disorders of psychological development

Inventors: Bruce J. Simon (Mountain Lakes, NJ); Joseph P. Errico (Warren, NJ); John T. Raffle (Austin, TX)
Assignee: ElectroCore, Inc.
A61N1/0456A61N1/0408A61N1/36025A61N1/36034A61N1/40A61N2/006A61N2/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,534,600
App. No.
16/662,140
Granted
Dec 27, 2022
Kind
B2
Abstract

Devices, systems and methods are disclosed for treating or preventing an autism spectrum disorder, a pervasive developmental disorder, or a disorder of psychological development. The methods comprise transmitting impulses of energy non-invasively to selected nerve fibers, particularly those in a vagus nerve. The nerve stimulation may be used as a behavior conditioning tool, by producing euphoria in an autistic individual. Vagus nerve stimulation is also used to modulate circulating serotonin levels in a pregnant woman so as to reduce the risk of having an autistic child; modulate the levels of growth factors within a child; promote balance of neuronal excitation/inhibition; modulate the activity of abnormal resting state neuronal networks; increase respiratory sinus arrhythmia; and avert episodes of motor stereotypies with the aid of forecasting methods.

Claims (17)

1. A device for treating or preventing a behavioral disorder in a patient, comprising:

a housing having a contact surface for contacting an outer skin surface of the of a neck of a patient;

a power source within the housing; and

wherein the power source generates and transmits an electric current through the contact surface and the outer skin surface of the neck to a vagus nerve within the patient non-invasively to generate an electrical impulse at the vagus nerve, wherein the electrical impulse is sufficient to modify the behavioral disorder in the patient, wherein the electrical impulse comprises bursts of about 2 to about 20 pulses with a silent intra-burst interval between each burst and wherein each burst has a frequency of about 1 to about 100 bursts per second.

2. The device of claim 1 further comprising an electrode within the housing coupled to the contact surface.

3. The device of claim 2 further comprising a conductor within the housing coupled to the electrode and the power source, wherein the power source generates and transmits the electric current through the conductor, electrode and the contact surface to the vagus nerve.

4. The device of claim 2 wherein the power source comprises a signal generator coupled to the electrode within the housing.

5. The device of claim 3 wherein the conductor is a first conductor, the device further comprising a second conductor coupling the electrode to the contact surface.

6. The device of claim 5 wherein the second conductor comprises an electrically conductive fluid within the housing between the electrode and the contact surface.

7. The device of claim 6 wherein the electrically conductive fluid comprises an electrically conductive gel.

8. The device of claim 1 wherein each pulse is about 50 to 1000 microseconds in duration.

9. The device of claim 1 the electrical current generates an electric field at the vagus nerve above a threshold for generating action potentials within A and B fibers of the vagus nerve and below a threshold for generating action potentials within C fibers of the vagus nerve.

10. The device of claim 1 wherein the electrical current generates an electric field at the vagus nerve above a threshold for generating action potentials within fibers of the vagus nerve responsible for activating neural pathways causing release of inhibitory neurotransmitters within a brain of the patient.

11. The device of claim 10 wherein the inhibitory neurotransmitters comprise GABA, norepinephrine, or serotonin.

12. The device of claim 1 wherein the behavioral disorder comprises attention-deficit hyperactivity disorder (ADHD).

13. The device of claim 1 wherein the behavioral disorder comprises an autism spectrum disorder.

14. The device of claim 1 wherein the behavioral disorder comprises Asperger syndrome.

Assignments (1)
SECURITY INTEREST Recorded Aug 12, 2025
From: ELECTROCORE, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 072452/0559 →
Continuity (16)
Division 13783319 · Mar 3, 2013
Continuation In Part 13731035 · Dec 30, 2012
Continuation In Part 13603781 · Sep 5, 2012
Continuation In Part 13222087 · Aug 31, 2011
Continuation In Part 13183765 · Jul 15, 2011
Continuation In Part 13183721 · Jul 15, 2011
Continuation In Part 13109250 · May 17, 2011
Continuation In Part 13075746 · Mar 30, 2011
Continuation In Part 13005005 · Jan 12, 2011
Continuation In Part 12964050 · Dec 9, 2010
Provisional Application 61488208 · May 20, 2011
Provisional Application 61487439 · May 18, 2011
Provisional Application 61471405 · Apr 4, 2011
Provisional Application 61451259 · Mar 10, 2011
Provisional Application 61415469 · Nov 19, 2010
Related Publication 20200054872A1 · Feb 20, 2020
Cited By (3)
US 12,377,260 US 12,475,761 US 12,598,433